Pfizer in the NEWS
 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) yesterday announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer . . .